Alerts will be sent to your verified email
Verify Email
FDC
|
FDC
|
Sanofi India
|
Bliss GVS Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Domestic Sales Growth - YoY
|
5.1 % | 1.7 % | n/a |
|
R&D as a % of Total Sales
|
2.22 % | 0.0 | 2.7 % |
|
Financials
|
|||
|
5 yr Average ROE
|
12.9 % | 50.34 % | 7.3 % |
|
5yr average Equity Multiplier
|
1.57 | 5.32 | 1.28 |
|
5yr Average Asset Turnover Ratio
|
0.55 | 0.42 | 0.64 |
|
5yr Avg Net Profit Margin
|
15.2 % | 22.84 % | 9.12 % |
|
Price to Book
|
2.68 | 10.33 | 4.38 |
|
P/E
|
23.67 | 24.98 | 40.45 |
|
5yr Avg Cash Conversion Cycle
|
-13.89 Days | -15.2 Days | 156.82 Days |
|
Inventory Days
|
61.89 Days | 67.68 Days | 53.4 Days |
|
Days Receivable
|
18.98 Days | 35.69 Days | 180.13 Days |
|
Days Payable
|
89.17 Days | 75.12 Days | 72.69 Days |
|
5yr Average Interest Coverage Ratio
|
90.41 | 777.41 | 14.96 |
|
5yr Avg ROCE
|
13.8 % | 23.73 % | 14.01 % |
|
5yr Avg Operating Profit Margin
|
17.7 % | 25.16 % | 16.55 % |
|
5 yr average Debt to Equity
|
0.0 | 0.0 | 0.08 |
|
5yr CAGR Net Profit
|
-2.41 % | 25.59 % | 53.73 % |
|
5yr Average Return on Assets
|
8.22 % | 9.68 % | 5.79 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
69.66 % | 60.4 % | 35.36 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
0.16 % | 0.0 | 0.32 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-1.8 % | -0.27 % | 0.0 |
|
FDC
|
Sanofi India
|
Bliss GVS Pharma
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
Therapeutic Area Wise Break-Up - Domestic
|
-
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|